FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809688907> ?p ?o ?g. }

• W2809688907 abstract "Slow-flow superficial vascular malformations (VMs) are rare congenital anomalies that can be responsible for pain and functional impairment. Currently, we have no guidelines for their management, which can involve physical bandages, sclerotherapy, surgery, anti-inflammatory or anti-coagulation drugs or no treatment. The natural history is progressive and worsening. Mammalian target of rapamycin (mTOR) is a serine/threonine kinase that acts as a master switch in cell proliferation, apoptosis, metabolism and angio/lymphangiogenesis. Sirolimus directly inhibits the mTOR pathway, thereby inhibiting cell proliferation and angio/lymphangiogenesis. Case reports and series have reported successful use of sirolimus in children with different types of vascular anomalies, with heterogeneous outcomes.The objective of this trial is to evaluate the efficacy and safety of sirolimus in children with complicated superficial slow-flow VMs.This French multicenter randomized observational-phase, phase 2 trial aims to include 50 pediatric patients 6 to 18 years old who have slow-flow (lymphatic, venous or lymphatico-venous) voluminous complicated superficial VM. Patients will be followed up for 12 months. All patients will start with an observational period (no treatment). Then at a time randomly selected between month 4 and month 8, they will switch to the experimental period (switch time), when they will receive sirolimus until month 12. Each child will undergo MRI 3 times: at baseline, at the switch time, and at month 12. For both periods (observational and treatment), we will calculate the relative change in volume of the VM divided by the study period duration. This relative change weighted by the study period duration will constitute the primary endpoint. VM will be measured by MRI images, which will be centralized and interpreted by the same radiologist who will be blinded to the study period. Hence, each patient will be his/her own control. Secondary outcomes will include assessment of safety and efficacy by viewing standardized digital photographs and according to the physician, the patient or proxy; impact on quality of life; and evolution of biological makers (coagulation factors, vascular endothelial growth factor, tissue factor).The main benefit of the study will be to resolve uncertainty concerning the efficacy of sirolimus in reducing the volume of VMs and limiting related complications and the safety of the drug in children with slow-flow VMs. This trial design is interesting in these rare conditions because all included patients will have the opportunity to receive the drug and the physician can maintain it after the end of the protocol if is found efficient (which would not be the case in a classical cross-over study).ClinicalTrials.gov Identifier: NCT02509468 , first received: 28 July 2015. EU Clinical Trials Register EudraCT Number: 2015-001096-43." @default.
• W2809688907 created "2018-07-10" @default.
• W2809688907 creator A5001564881 @default.
• W2809688907 creator A5002722711 @default.
• W2809688907 creator A5003175013 @default.
• W2809688907 creator A5005052958 @default.
• W2809688907 creator A5005693498 @default.
• W2809688907 creator A5008587420 @default.
• W2809688907 creator A5010899888 @default.
• W2809688907 creator A5011408077 @default.
• W2809688907 creator A5018171524 @default.
• W2809688907 creator A5018464286 @default.
• W2809688907 creator A5026660441 @default.
• W2809688907 creator A5031452363 @default.
• W2809688907 creator A5042438814 @default.
• W2809688907 creator A5043446323 @default.
• W2809688907 creator A5048312024 @default.
• W2809688907 creator A5053839055 @default.
• W2809688907 creator A5059416542 @default.
• W2809688907 creator A5065380648 @default.
• W2809688907 creator A5065871425 @default.
• W2809688907 creator A5070506825 @default.
• W2809688907 creator A5080253786 @default.
• W2809688907 creator A5080398125 @default.
• W2809688907 creator A5082030833 @default.
• W2809688907 creator A5083661496 @default.
• W2809688907 creator A5089979015 @default.
• W2809688907 creator A5090924104 @default.
• W2809688907 date "2018-06-27" @default.
• W2809688907 modified "2023-10-10" @default.
• W2809688907 title "Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design" @default.
• W2809688907 cites W1502172390 @default.
• W2809688907 cites W1706136667 @default.
• W2809688907 cites W1984838366 @default.
• W2809688907 cites W1988673699 @default.
• W2809688907 cites W2000239178 @default.
• W2809688907 cites W2013666706 @default.
• W2809688907 cites W2051934010 @default.
• W2809688907 cites W2057600556 @default.
• W2809688907 cites W2089597911 @default.
• W2809688907 cites W2094826099 @default.
• W2809688907 cites W2096991001 @default.
• W2809688907 cites W2119281015 @default.
• W2809688907 cites W2119406490 @default.
• W2809688907 cites W2120470778 @default.
• W2809688907 cites W2120627213 @default.
• W2809688907 cites W2122127644 @default.
• W2809688907 cites W2145430240 @default.
• W2809688907 cites W2153601997 @default.
• W2809688907 cites W2155439939 @default.
• W2809688907 cites W2164226203 @default.
• W2809688907 cites W2222512782 @default.
• W2809688907 cites W2282181553 @default.
• W2809688907 cites W2392938395 @default.
• W2809688907 cites W3141179634 @default.
• W2809688907 doi "https://doi.org/10.1186/s13063-018-2725-1" @default.
• W2809688907 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6020321" @default.
• W2809688907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29945674" @default.
• W2809688907 hasPublicationYear "2018" @default.
• W2809688907 type Work @default.
• W2809688907 sameAs 2809688907 @default.
• W2809688907 citedByCount "19" @default.
• W2809688907 countsByYear W28096889072019 @default.
• W2809688907 countsByYear W28096889072020 @default.
• W2809688907 countsByYear W28096889072021 @default.
• W2809688907 countsByYear W28096889072022 @default.
• W2809688907 countsByYear W28096889072023 @default.
• W2809688907 crossrefType "journal-article" @default.
• W2809688907 hasAuthorship W2809688907A5001564881 @default.
• W2809688907 hasAuthorship W2809688907A5002722711 @default.
• W2809688907 hasAuthorship W2809688907A5003175013 @default.
• W2809688907 hasAuthorship W2809688907A5005052958 @default.
• W2809688907 hasAuthorship W2809688907A5005693498 @default.
• W2809688907 hasAuthorship W2809688907A5008587420 @default.
• W2809688907 hasAuthorship W2809688907A5010899888 @default.
• W2809688907 hasAuthorship W2809688907A5011408077 @default.
• W2809688907 hasAuthorship W2809688907A5018171524 @default.
• W2809688907 hasAuthorship W2809688907A5018464286 @default.
• W2809688907 hasAuthorship W2809688907A5026660441 @default.
• W2809688907 hasAuthorship W2809688907A5031452363 @default.
• W2809688907 hasAuthorship W2809688907A5042438814 @default.
• W2809688907 hasAuthorship W2809688907A5043446323 @default.
• W2809688907 hasAuthorship W2809688907A5048312024 @default.
• W2809688907 hasAuthorship W2809688907A5053839055 @default.
• W2809688907 hasAuthorship W2809688907A5059416542 @default.
• W2809688907 hasAuthorship W2809688907A5065380648 @default.
• W2809688907 hasAuthorship W2809688907A5065871425 @default.
• W2809688907 hasAuthorship W2809688907A5070506825 @default.
• W2809688907 hasAuthorship W2809688907A5080253786 @default.
• W2809688907 hasAuthorship W2809688907A5080398125 @default.
• W2809688907 hasAuthorship W2809688907A5082030833 @default.
• W2809688907 hasAuthorship W2809688907A5083661496 @default.
• W2809688907 hasAuthorship W2809688907A5089979015 @default.
• W2809688907 hasAuthorship W2809688907A5090924104 @default.
• W2809688907 hasBestOaLocation W28096889071 @default.
• W2809688907 hasConcept C126322002 @default.
• W2809688907 hasConcept C141071460 @default.
• W2809688907 hasConcept C168563851 @default.
• W2809688907 hasConcept C23131810 @default.
• W2809688907 hasConcept C2775965419 @default.

• next